Litigation Details for Picone v. Shire U.S. Inc. (Indirect Purchaser Antitrust Class Action) (D. Mass. 2016)
✉ Email this page to a colleague
Picone v. Shire U.S. Inc. (Indirect Purchaser Antitrust Class Action) (D. Mass. 2016)
| Docket | ⤷ Try a Trial | Date Filed | 2016-11-22 |
| Court | District Court, D. Massachusetts | Date Terminated | 2022-01-25 |
| Cause | 28:1332 Diversity-Property Damage | Assigned To | Allison Dale Burroughs |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 6,287,599; 6,811,794 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Picone v. Shire U.S. Inc. (Indirect Purchaser Antitrust Class Action)
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Picone v. Shire U.S. Inc. (Indirect Purchaser Antitrust Class Action) (D. Mass. 2016)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2016-11-22 | 1 | method-of-use patent, and U.S. Patent Nos. 6,287,599 (‘599 Patent) and 6,811,794 (‘794 Patent), which cover…Shire’s Intuniv patent portfolio consists of U.S. Patent Nos. 5,854,290 (‘290 Patent), which is a now-invalidated…applied a patent procurement strategy known as “evergreening.” “Evergreened” patents are patents not on …method-of-use patent (‘290 Patent) of guanfacine hydrochloride and two extended release formulation patents (‘599…-of-Use Patent 57. Shire asserted all three (3) patents, including the ‘290 Patent, against | External link to document | |
| 2017-10-31 | 102 | 5,854,290 (the ’290 patent), 6,287,599 (the ’599 patent), and 6,811,794 (the ’794 patent), the terms of which…5,854,290 (the ’290 patent), 6,287,599 (the ’599 patent), and 6,811,794 (the ’794 patent), the terms of which…that ’290 patent was a method-of-use patent. Shire denies any characterization of those patents, and denies…under three patents that covered Intuniv and that were listed in the Orange Book: U.S. Patent Nos. 5,854,290…under three patents that cover Intuniv and that were listed in the Orange Book: U.S. Patent Nos. 5,854,290 | External link to document | |
| 2020-10-09 | 343 | Memorandum & Order | “the ’290 Patent”), 4 6,287,599 (“the ’599 Patent”), 5 and 6,811,794 (“the ’794 Patent” and, collectively…collectively with the ’290 Patent and the ’599 Patent, “the Patents”). 6 [FWK 380-1 ¶ 26; FWK 374-1 ¶ 3]. …hearing on the Patents on February 14, 2012. [FWK No. 380-1 ¶ 37]. The ’599 Patent and ’794 Patent each reference…Shire listed three patents in the FDA Orange Book as covering Intuniv: U.S. Patent Nos. 5,854,290 (“the…’290 Patent in March 2012. [FWK 380-1 ¶ 27; FWK 374-1 ¶ 19]. Plaintiffs maintain that the patent was abandoned | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
